Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

NCT02959970 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT02959970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02959970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Lead sponsor
Almirall, S.A.
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2016
Completion date
March 9, 2018
Enrollment
100 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris